Early Th2 inflammation in the upper respiratory mucosa as a predictor of severe COVID-19 and modulation by early treatment with inhaled corticosteroids: a mechanistic analysis
Jonathan Baker(Lung Institute), Mona Bafadhel(National Institute for Health and Care Excellence), Sanjay Ramakrishnan(The University of Western Australia), Steven P. Cass(National Institute for Health Research), Louise Donnelly(Lung Institute), Richard Russell(Southern Health NHS Foundation Trust), Mahdi Mahdi(National Institute for Health and Care Research), Jodie L. Simpson(Hunter Medical Research Institute), Peter J. Barnes(Imperial College London), Dan V. Nicolau(Queensland University of Technology)
Cited by 58
Related Papers
The cytokine network in asthma and chronic obstructive pulmonary disease
|Journal of Clinical Investigation|2008|968
Inflammatory subtypes in asthma: Assessment and identification using induced sputum
|Respirology|2006|939
Outcomes for COPD pharmacological trials: from lung function to biomarkers
|European Respiratory Journal|2008|856
How corticosteroids control inflammation: Quintiles Prize Lecture 2005
|British Journal of Pharmacology|2006|812
Chronic obstructive pulmonary disease
|Nature Reviews Disease Primers|2015|733